Novacyt S.A. ("Novacyt", the "Company" or the "Group")

Launch of CE-Mark test to detect multiple COVID-19 variants of concern - Seite 3

RUO

R00130

SNPsig SARS-CoV-2 (20H/501Y.V2)

20H/501Y.V2

R00135

SNPsig SARS-CoV-2 (20J/501Y.V3)

20J/501Y.V3

R00134

SNPsig SARS-CoV-2 (20B/S.484K)^*

20B/S.484K

R00147

SNPsig SARS-CoV-2 (N501Y)

Variants with the N501Y mutation (20I/501Y.V1, 20H/501Y.V2, 20J/501Y.V3)

R00131

SNPsig SARS-CoV-2 (E484K)

Variants with the E484K mutation (20I/501Y.V1, 20H/501Y.V2, 20J/501Y.V3, 20C/S.452R)

R00132

^#Will be launched w/c 22 March 2021

^*Will be launched w/c 29 March 2021

References:

1. World Health Organization. COVID-19 Weekly Epidemiological Update. World Health Organization 1–3. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update- ... (2021).
2. World Health Organization. Weekly epidemiological update - 25 February 2021. World Health Organization 1–3 Available from: https://www.who.int/publications/m/item/covid-19-weekly-epidemiologica ... (2021).
3. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell [Internet]. 2020;182(5):1295-1310.e20. Available from: http://dx.doi.org/10.1016/j.cell.2020.08.012
4. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Finkin S, Schaefer-Babajew D, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 2 3. bioRxiv [Internet]. 2021 [cited 2021 Jan 25]; Available from: https://doi.org/10.1101/2021.01.15.426911
5. Novavax Inc. - IR Site. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial [Internet]. [cited 2021 Feb 1]. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covi ...
6. Johnson | Johnson & Johnson. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial [Internet]. [cited 2021 Feb 1]. Available from: https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covi ...
7. Andreano E, Piccini G, Licastro D, Casalino L, Johnson N V, Paciello I, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv [Internet]. 2020;2020.12.28.424451. Available from: http://biorxiv.org/content/early/2020/12/28/2020.12.28.424451.abstract
8. Horby, A. P. et al. NERVTAG - Presented to SAGE on 21/1/21. https://assets.publishing.service.gov.uk/government/uploads/system/upl ... (2021)
9. Greaney AJ, Loes AN, Crawford KH, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. [cited 2021 Jan 19]; Available from: https://doi.org/10.1101/2020.12.31.425021
10. Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medRxiv [Internet]. 2021 [cited 2021 Jan 25];1–19. Available from: https://www.medrxiv.org/content/10.1101/2021.01.26.21250224v1
11. COG-UK. COG-UK report on SARS-CoV-2 Spike mutations of interest in the UK [Internet]. Vol. 1. 2021. Available from: https://cov-lineages.org/global_report.html
12. Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv [Internet]. 2021 [cited 2021 Jan 29]; Available from: https://doi.org/10.1101/2021.01.25.427948